Patents Examined by Benjamin J Packard
-
Patent number: 12263238Abstract: Compositions and methods for styling the hair are provided. The compositions improve the curl definition, softness, smoothness, sensory feel, and/or frizz control to the hair. Also provided are methods of using the compositions.Type: GrantFiled: September 30, 2022Date of Patent: April 1, 2025Assignee: L'OREALInventors: Stephanie Laga, Allison Perner
-
Patent number: 12257241Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.Type: GrantFiled: October 20, 2023Date of Patent: March 25, 2025Assignee: BIOVERSYS AGInventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
-
Patent number: 12257308Abstract: Described herein are thermally responsive polymer-therapeutic molecule conjugates comprising a therapeutic molecule conjugated to a thermally responsive polymer with an acrylate, methacrylate, acrylamide, and/or methacrylamide backbone and a plurality of oligoethylene glycol side chains.Type: GrantFiled: April 30, 2019Date of Patent: March 25, 2025Assignee: Duke UniversityInventors: Ashutosh Chilkoti, Imran Ozer
-
Patent number: 12257262Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.Type: GrantFiled: December 17, 2021Date of Patent: March 25, 2025Assignees: Board of Regents, The University of Texas System, Moleculin Biotech, Inc.Inventors: Donald Picker, Waldemar Priebe
-
Patent number: 12251470Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.Type: GrantFiled: November 8, 2019Date of Patent: March 18, 2025Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Adam Judge, Kieu Mong Lam, Lorne Ralph Palmer, Petra Schreiner
-
Patent number: 12251471Abstract: Disclosed herein are embodiments of a nanoparticle composition suitable for delivering a therapeutic agent to a subject by nebulization. The nanoparticle comprises an ionizable lipid, cholesterol or a derivative thereof, a structural lipid, and a PEG lipid. The nanoparticle may partially or completely encapsulate a therapeutic agent, and may be nebulized for administration, such as by inhalation. In some embodiments, the therapeutic agent is mRNA.Type: GrantFiled: July 25, 2022Date of Patent: March 18, 2025Assignee: Oregon State UniversityInventors: Jeonghwan Kim, Gaurav Sahay
-
Patent number: 12246098Abstract: The present invention relates to trans-epithelial membrane delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin and mucosa previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures or cleaves molecules of the basement membrane of the epithelial membrane. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the outer layers of the epithelial membrane. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to smooth muscle.Type: GrantFiled: March 13, 2024Date of Patent: March 11, 2025Assignees: BioPhysics Pharma, Inc.Inventors: John J. Masiz, Zhen Zhu
-
Patent number: 12239708Abstract: A dry powder inhalation formulation includes at least one active pharmaceutical ingredient (API) and a lipid matrix having at least one triglyceride chosen in the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and their mixture and its manufacturing method.Type: GrantFiled: December 27, 2019Date of Patent: March 4, 2025Assignee: UNIVERSITÉ LIBRE DE BRUXELLESInventors: Karim Amighi, Nathalie Wauthoz, Rémi Rosière
-
Patent number: 12233152Abstract: The subject invention provides materials and methods for improving facial skin, hair and scalp health using cosmetic yeast-based masks. In a specific embodiment, the subject invention provides a yeast-based mask for application to the face, which can improve the health and appearance of thereof. In another specific embodiment, the subject invention provides a yeast-based mask for application to the hair and scalp, which can aid in preventing hair loss, as well as improve the health and appearance of the hair and scalp. Methods of using the yeast-based masks are also provided.Type: GrantFiled: August 10, 2023Date of Patent: February 25, 2025Assignee: LOCUS SOLUTIONS IPCO, LLCInventors: Sean Farmer, Ken Alibek
-
Patent number: 12226533Abstract: Silica modified vaterite Janus nanoparticles are provided, together with methods for the synthesis of such particles. The disclosed methods make use of a Pickering emulsion, in a scalable aqueous process. The silica-modified surface is amenable to chemical modification, for example with physiologically acceptable labels.Type: GrantFiled: December 2, 2019Date of Patent: February 18, 2025Assignee: UTI LIMITED PARTNERSHIPInventors: Giovanniantonio Natale, Harsovin Kaur
-
Patent number: 12226531Abstract: The present invention relates to a composition for feeding a ruminant comprising i) a non-protein nitrogen compound, and ii) a coating surrounding the non-protein nitrogen compound, wherein said coating comprises one or more layers of a mixture of a saturated fat and a fatty acid, and said coating comprises from 60 wt.-%+/?10% to 85 wt.-%+/?10% of the saturated fat, e.g. hydrogenated fat, and from 15 wt.-%+/?10% to 40 wt.-%+/?10% of the fatty acid, each based on the total weight of the coating; a process for the preparation of said composition and its uses, e.g., for improving nitrogen utilization in a ruminant.Type: GrantFiled: September 27, 2018Date of Patent: February 18, 2025Assignee: Evonik Operations GmbHInventors: Thomas Haeussner, Frank Fischer, Georg Borchers, Ulrike Kottke, Christoph Kobler, Cornelia Borgmann, Karsten Portner
-
Patent number: 12220466Abstract: A pharmaceutical formulation for topical dental administration or medical (e.g., implant) treatment, including effective amounts of: at least one antimicrobial compound; at least one peroxide source compound; and at least one gel agent. Also disclosed are methods of oral anatomy treatment. The pharmaceutical formulation and treatment methods provide the patient with oral anatomy benefits including, for example, decreased or arrested gum recession; decreased or arrested bone recession; decreased or arrested bone mass loss; decreased or eliminated pain; decreased or eliminated bleeding; decreased or eliminated swelling; enhanced regeneration of bone; enhanced soft tissue repair; or a combination thereof.Type: GrantFiled: May 24, 2024Date of Patent: February 11, 2025Inventor: Larry P. Bleier
-
Patent number: 12220482Abstract: An object of the present invention is to provide a liposome composition containing a liposome having an excellent leakage rate of a nucleic acid analog anticancer agent, and a method for producing the same. According to the present invention, there are provided a liposome composition containing a liposome which (1) contains a nucleic acid analog anticancer agent and in which (2) a content ratio of a lysophospholipid contained in a lipid forming the liposome with respect to a total amount of phospholipids other than the lysophospholipid contained in the lipid forming the liposome is 0.01 mol % to 5 mol % and (3) a nucleic acid analog anticancer agent/lipid ratio is 2 mass % to 10 mass %, and a method for producing the same.Type: GrantFiled: January 4, 2021Date of Patent: February 11, 2025Assignee: FUJIFILM CorporationInventors: Takahiro Sekiguchi, Mikinaga Mori, Kentaro Numajiri, Hiroyuki Kitaoka
-
Patent number: 12220493Abstract: The present disclosure provides wound dressing compositions that stimulate nitric oxide production in a wound upon application. The wound dressing composition includes a first layer comprising collagen and an oxidized cellulose and a second layer comprising a nitrite source. Also disclosed herein are kits comprising the wound dressing compositions of the present technology.Type: GrantFiled: July 15, 2019Date of Patent: February 11, 2025Assignee: Systagenix Wound Management, LimitedInventors: Alexander Waite, Carrina Ward
-
Patent number: 12220483Abstract: The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.Type: GrantFiled: March 18, 2024Date of Patent: February 11, 2025Assignee: Pharmosa Biopharm Inc.Inventors: Pei Kan, Yi Fong Lin, Ko Chieh Chen
-
Patent number: 12213480Abstract: A dry biocidal absorbent composition comprises an interspersed mixture of a dry absorbent silicate mineral material and a dry biocide. The absorbent silicate mineral material may comprise expanded perlite and/or exfoliated vermiculite. The biocide may comprise sodium dichloroisocyanurate or a hydrate thereof. The composition may be used for cleaning up a bodily spill from a floor or other surface.Type: GrantFiled: November 27, 2019Date of Patent: February 4, 2025Inventor: David Lilly
-
Patent number: 12203831Abstract: Disclosed herein are compositions and methods for removing interfering substances from biological samples, biochemical assays, or reagents used in biological samples using porous liposomes that capture and in some instances enrich said interfering substances within the liposomes.Type: GrantFiled: September 23, 2019Date of Patent: January 21, 2025Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Frank Vitzthum, Huey Lee, Michelle Son
-
Patent number: 12201710Abstract: A hydrophilic silica/polymer blend is provided comprising (a) a hydrophilic silica powder; and (b) a thickening polymer powder, comprising (i) structural units of C4-8 alkyl (meth)acrylate monomer; (ii) structural units of (meth)acrylic acid monomer; (iii) structural units of (methoxy) poly(ethylene glycol) (meth)acrylate monomer; and (iv) structural units of multiethylenically unsaturated monomer; wherein the weight ratio of hydrophilic silica powder to thickening polymer powder in the hydrophilic silica/polymer blend is 1:9 to 9:1. Also provided are personal care compositions containing same and methods of using same.Type: GrantFiled: April 16, 2020Date of Patent: January 21, 2025Assignees: Dow Global Technologies LLC, Rohm and Haas CompanyInventors: Luqing Qi, Liang Chen, Lu Bai, Lyndsay M. Leal, David M. Meunier, Yunshen Chen, Fanwen Zeng
-
Patent number: 12203122Abstract: Processes for transesterifying wax esters. Implementations may include: providing a feedstock including wax esters, contacting the feedstock with a lipase, and catalytically transesterifying the wax esters in the feedstock with the lipase to form a transesterified product. An oxidative stability index (OSI) of the transesterified product may be greater than an OSI of the feedstock.Type: GrantFiled: January 26, 2023Date of Patent: January 21, 2025Assignee: CARGILL, INCORPORATEDInventors: Jeff Addy, James H. Brown, Clay Daly
-
Patent number: 12194017Abstract: Methods, compositions of matter, and devices for delivering a therapeutic composition to a heart of a subject using a biopolymer scaffold material are described. In some embodiments, the biopolymer scaffold material including the therapeutic composition may be attached to a first cardiac tissue of a subject. The therapeutic composition is delivered from the biopolymer scaffold material to the heart of the subject.Type: GrantFiled: August 24, 2022Date of Patent: January 14, 2025Assignee: Helios Cardio Inc.Inventors: Kevin Cornwell, Yiannis Monovoukas, Peter Jackson, Clayton Kaiser